Vyvgart Hytrulo received FDA approval on June 20, 2023. It is approved for the treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

Suflave was approved by the FDA on June 15, 2023. It is a prescription laxative used to cleanse the bowel in preparation for colonoscopy in adults.

The US Food and Drug Administration (FDA) approved Posluma injection on May 25, 2023.

durlobactam/sulbactam, marketed under the brand name Xacduro, is FDA approved. The approval was granted on May 23, 2023.

Yes, epcoritamab, marketed under the brand name Epkinly, is FDA approved. It received approval on May 19, 2023.

Beremagene geperpavec topical, marketed under the brand name Vyjuvek, is an FDA-approved medication for treating wounds caused by dystrophic epidermolysis bullosa (DEB).

Perfluorohexyloctane ophthalmic, marketed under the brand name Miebo, is an FDA-approved medication for treating dry eye disease.

Fezolinetant, sold under the brand name Veozah, was approved by the FDA on May 12, 2023.

The FDA approved Arexvy on May 3, 2023. It is the first respiratory syncytial virus (RSV) vaccine approved for older adults.

The FDA approved VOWST on April 26, 2023, for the prevention of recurrence of Clostridioides difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI.

Yes, Tofersen, marketed under the brand name Qalsody, received FDA approval on April 25, 2023.

Omidubicel, marketed under the brand name Omisirge, is FDA approved. The FDA granted approval on April 17, 2023.